idl-2965

IDL-2965 is a selective, orally available small molecule integrin antagonist developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other serious fibrotic diseases. It targets RGD-binding integrins, specifically inhibiting αvβ1, αvβ3, and αvβ6 integrins with high potency. By blocking these integrins, IDL-2965 disrupts multiple fibrogenic processes including local activation of TGF-β (a central regulator of pathological fibrosis), fibroblast migration, and myofibroblast survival. Preclinical studies have demonstrated robust antifibrotic activity across various organ systems at low oral doses with a favorable safety profile. Clinical development has included Phase 1 trials in healthy subjects and patients with IPF and non-alcoholic steatohepatitis (NASH)[1][2][3][5].

Other names

idl 2965idl2965idl-2965